Key Takeaways Regeneron shares have jumped 21.5% YTD on positive pipeline and regulatory updates.Eylea HD approvals and rising demand help counter pressure from competing ophthalmology therapies.Label expansions for Libtayo and strong Dupixent sales continue to support Regeneron's top-line growth.Shares of Regeneron Pharmaceuticals (REGN) have gained 21.5% year to date compared with the industry’s growth of 10.2%. The stock has also outperformed the sector and the S&P 500 Index during this time frame.The ra ...

Key Takeaways VKTX shares rose 34% in three months on momentum around its investigational obesity drug VK2735.Viking hit fast enrollment milestones for phase III VANQUISH-1 and phase II VENTURE-Oral studies.Viking is also enrolling the VANQUISH-2 study, targeting completion of recruitment in early 2026.Shares of Viking Therapeutics (VKTX) have surged 34% in the past three months, primarily driven by positive investor expectations around its investigational obesity drug, VK2735.Last month, Viking announced t ...

All right, this just coming at us. We've got a new announcement of a deal with the United Kingdom. Edward Lawrence at the White House.Is this about pharmaceuticals. It >> it is. This is a pharmaceutical deal.The United Kingdom, it's a framework agreement basically in line with sort of the trade agreements that we're making, but this is specifically pharmaceuticals. The United Kingdom agrees to pay 25% more for new medicines coming online there so we can have savings here in the United States. and then the U ...

礼来与诺和诺德的价格竞争策略 - 礼来公司宣布降低Zepbound起始剂量现金支付价格，首次起始剂量降价50美元，第二次起始剂量降价幅度更大[1][3] - 诺和诺德同样采取起始剂量折扣策略，几周前已对前两个月的治疗费用进行进一步降价[3] - 两家公司均保持较高治疗剂量的价格不变，折扣主要针对起始剂量阶段[3][4] 药物定价结构与市场策略 - 起始剂量（如Zepbound 5毫克）用于帮助患者适应药物副作用，并非经试验证明的有效治疗剂量[2][5] - 治疗剂量（如Zepbound 7.5毫克）是经临床试验验证能发挥医疗效果的剂量，此阶段价格未发生变化[4][5] - 通过起始剂量折扣吸引患者尝试，使其体验减肥效果后继续支付全额治疗费用[5] 行业竞争格局与未来趋势 - 口服剂型药物预计将于明年上市，礼来和诺和诺德均在开发自有版本[9][10] - 口服药物起始剂量价格预计将大幅降低至每月约150美元，这将给整个品类带来额外定价压力[9][10] - 口服药物的推出可能开辟全新患者市场，但目前注射剂需求极高，患者转换意愿尚不明确[11] 支付环境与政策影响 - 保险覆盖范围仍不完善，许多保险公司目前不承保此类药物，迫使药企直接提供折扣[8] - 礼来和诺和诺德上月与特朗普政府达成协议，从明年开始降低这些药物的价格[7] - 行业期望通过政府协议使折扣更普遍，价格能够全面下降[7]

药品降价措施 - 礼来公司通过其LillyDirect平台降低Zepbound自付费用 最低单剂量小瓶月费用降至299美元 较原价349美元下降14% [1][2] - 礼来公司5毫克剂量Zepbound月费用降至399美元 较原价499美元下降约20% 75毫克至15毫克剂量月费用降至449美元 原价为499美元 [2] - 诺和诺德公司将Ozempic和Wegovy的自付月费用从499美元降至349美元 两种药物最低剂量在前两个月月费用为199美元 [3] 市场反应 - 降价公告后礼来公司股价在盘前交易中下跌近1% [3] - 诺和诺德公司股价在盘前交易中下跌超过17% [3]

ALK (ALKB:DC / OMX: ALK B) today announced the appointment of Edward Jordan as new Executive Vice President (EVP) and head of Commercial Operations in North America as per 5 January 2026. Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s Allergy+ strategy. Edward Jordan, an Ame ...

Investing for passive income can be more reliable than investing for pure appreciation.If you are new to investing, then exchange-traded funds (ETFs) may be a good place to start your journey. That's because they are highly liquid, essentially trade like stocks, and provide diversification, as ETFs hold a basket of stocks.ETFs can also pay dividends. Many more risk-averse investors prefer to pursue dividend stocks because they can provide passive income every year, often in a more reliable manner than inves ...

NESS ZIONA, Israel, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will participate in the 8th Annual Evercore Annual Healthcare Conference, to take place December 2-4, 2025, in Miami, Florida. Mapi is actively seeking additional partnerships for its new proprietary Depot products. Company management will be available for one-on-one meetings during the ...

PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT), where he lea ...

OCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET.  As part of the event, Equels will participate in a moderated “fireside” chat that will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing DURIPANC clinical tr ...